Based on a real-world cohort of patients with a diverse ethnic background, this study is also the first, to our knowledge, to assess the benefit of integrating reflex somatic testing in the clinical workflow and the first to report the prevalence of actionable and nonactionable FGFR1-4 alterations fulfilling CAP/ASCO/AMP reporting criteria.17 A prior study by Fischbach and colleagues28 focused on FGFR amplifications and found a rate of 3.4% in a cohort of 153 bladder tumors. The gene discussed is FGFR1; the disease is urinary bladder neoplasm.